Neumora Therapeutics, Inc. (NMRA) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

45NeutralDD: Jun 19, 2026Analyst: 58

paidPrice at analysis date

USD 1.48 (19/06/2026)

domainMkt cap

$274M

pie_chartShares

185M

candlestick_chart52W

$0.61-$3.65

trending_downShort interest

3.9%

MEDIUMNASDAQHealth Care96 employeesFounded 2019

Verdict: Moderately Attractive — Optionality biotech, asymmetry priced-in

Post Phase 3 KOASTAL (navacaprant) failure in May 2026, the stock collapsed ~70% and re-rated near a cash floor of ~$0.79/share. The 35% workforce cut extended runway into Q3 2027 and the remaining pipeline (NMRA-511 Alzheimer's agitation, NMRA-898 schizophrenia, NMRA-215 obesity) keeps optionality alive. At $1.48 the market is already pricing in cash + early-stage rNPV: the asymmetric window has narrowed vs the $0.91 trough but binary catalysts in H2 2026 / Q4 2026 still offer skewed upside if data hits.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-06-19

Neumora Therapeutics (NMRA)

CNS biotech · NASDAQ · Watertown, MA

"Cash-anchored optionality after navacaprant failure: floor solid, upside binary."

Net cash > 50% mkt cap Phase 3 lead failed Runway into Q3 2027 Binary catalysts H2 2026 Zero debt

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value Estimate — Net Cash + rNPV pipeline (SotP)

Fair value base case

USD 1.35

Range: USD 0.80-USD 4.50

Price at analysis date: USD 1.48 (19/06/2026)

Base upside/downside: -9%

Methodology: Probability-weighted FV = 0.20×$4.25 + 0.50×$1.35 + 0.30×$0.70 = $1.74 expected value, but base case ($1.20–$1.35) is what is built into a normal-execution scenario. Implied EV/Cash at base FV ≈ 0.7x, within peer range (0.45–0.95x). Cross-check vs SOTP NPV models cited by Leerink ($8 PT) and William Blair ($7.62 NPV) shows market has not yet re-rated to consensus — analysts assume higher POS than this DD's base case. Sensitivity: each 5pp uplift in NMRA-511 POS adds ~$0.15/share. ⚠️ Not investment advice.

Component	Assumption	USD/share
Net cash (forward 12M)	$147.1M Q1'26 − ~$45M H2'26 burn = $102M / 185M sh.	+0.55
NMRA-511 rNPV (AD agitation)	$500M peak sales × 18% POS (Phase 1b+) × 0.45 NPV factor / 185M sh.	+0.55
NMRA-898 rNPV (schizophrenia)	$400M peak × 8% POS × 0.45 NPV factor / 185M sh.	+0.15
NMRA-215 rNPV (obesity-CNS)	$300M peak × 5% POS × 0.40 NPV factor / 185M sh.	+0.05
G&A drag & legal reserve	Post-restructure opex erosion + potential securities litigation reserve (NPV)	−0.10
FV base case	Sum of components above (0.55+0.55+0.15+0.05−0.10)	≈ $1.20

Bull

$3.50–$5.00

Probability: 20%

NMRA-511 Phase 1 MAD (Q4 2026) confirms unsurpassed effect in AD agitation; partnership/licensing deal (M&A interest re-emerges); POS to 35–40%, peak sales $800M–$1.2B. NMRA-898 schizophrenia signal positive H2 2026.

Base

$1.10–$1.60

Probability: 50%

NMRA-511 advances normally with mixed signals; NMRA-898 readout neutral/inconclusive; cash erosion as runway shortens. Stock trades within $0.05 of forward cash floor + modest pipeline credit.

Bear

$0.55–$0.85

Probability: 30%

NMRA-511 MAD shows tolerability/efficacy weakness; NMRA-898 negative; further restructuring; securities class action settlement diluting cash floor; stock converges to ~0.7x net cash post-burn.

Methodology: Methodology: Probability-weighted FV = 0.20×$4.25 + 0.50×$1.35 + 0.30×$0.70 = $1.74 expected value, but base case ($1.20–$1.35) is what is built into a normal-execution scenario. Implied EV/Cash at base FV ≈ 0.7x, within peer range (0.45–0.95x). Cross-check vs SOTP NPV models cited by Leerink ($8 PT) and William Blair ($7.62 NPV) shows market has not yet re-rated to consensus — analysts assume higher POS than this DD's base case. Sensitivity: each 5pp uplift in NMRA-511 POS adds ~$0.15/share. ⚠️ Not investment advice. Not investment advice.

warning

🚨 Post Phase 3 failure — pipeline now built around early-stage assets

In May 2026 Neumora announced KOASTAL-2 and KOASTAL-3 (navacaprant) failed primary and key secondary endpoints in major depressive disorder; the program was discontinued and a 35% workforce reduction was enacted. The investment case is now anchored on (i) cash floor ($147.1M cash, no debt, runway into Q3 2027) and (ii) optionality on three early-stage CNS assets with no revenue. Investors must be comfortable underwriting a pre-revenue biotech rebuild story.

⚠️ Methodology note: Pre-revenue clinical-stage biotech. Fair value built on Net Cash + risk-adjusted NPV (rNPV) of remaining pipeline (Step 2 profile "Biotech/Medtech pre-approval"). EV/Revenue, EV/EBITDA and DCF are not applicable. Probabilities of success (POS) based on stage-adjusted industry benchmarks (Phase 1: 8–15%; Phase 1b positive signal: 18–25%).

📊 Capital Structure · Short Interest · Buyback & Dilution

🟡 Short Interest

3.9%

~5.0M shares short of ~128M float. Interpretation: low conviction short positioning; not a squeeze candidate. Days to cover ~1d on avg volume 5.2M.

🟡 Share dilution (1Y)

+1.4%

From ~180M to ~185M shares (organic SBC issuance only). No equity raise YTD; shelf registration likely active but unused given cash position.

🔴 Buyback

No buyback authorization. Capital allocation prioritizes pipeline funding and cash preservation through Q3 2027 runway.

Short Interest — context

NMRA — 3.9%

3.9%

Short interest is low post-failure: the major short thesis (navacaprant miss) has already played out. Limited squeeze potential. Insider transactions in last 12 months: CFO and CEO compensation grants documented; no material insider open-market buying reported post-failure (a missed signal — would have indicated insider confidence in pipeline).

$Financial analysis — FY 2025 / Q1 2026

Cash & equivalents

$147.1M

Mar-31-2026 · runway into Q3 2027

Q1 2026 net loss

$56M

EPS (0.30) vs (0.31) consensus

Debt

$0M

Zero financial debt

Quarterly burn (post-cut)

~$15M

35% workforce reduction May 2026

Item	FY2023	FY2024	FY2025	FY2026E	Guidance 2027
Revenue ($M)	0.0	0.0	0.0	0.0	0.0
R&D expense ($M)	175	195	210	~140	~90
G&A expense ($M)	50	62	68	~55	~40
Net loss ($M)	−210	−240	−255	−185	−115
Cash EoP ($M)	425	305	180	~100	~30
Shares out (M)	160	175	183	185	188

Notes: FY2026E reflects 35% workforce cut from late May; full benefit captured in 2027. Cash EoP 2026/2027 estimates assume no equity raise; Q3 2027 runway implies an equity event by then. No revenue forecast — first commercial product not before 2030.

Quarterly dynamics — last 5 quarters
Metric	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue ($M)	0.0	0.0	0.0	0.0	0.0
R&D expense ($M)	48	52	55	55	52
Net loss ($M)	−58	−62	−68	−67	−56
End-of-period cash ($M)	300	250	220	180	147

Financial position and sustainability

Cash runway (months)

~17 mo

Net cash / Mkt cap

54%

Pipeline rNPV / Mkt cap

46%

Discount to pre-failure peak

−92% vs IPO

account_tree

Business model — Clinical-stage CNS / neuroscience biotech

Neumora's post-failure pipeline

Neumora was built on the thesis of bringing precision-medicine biomarker-driven CNS therapeutics to depression, agitation, schizophrenia and obesity. The May 2026 KOASTAL Phase 3 failure of navacaprant (lead asset) reset the company to a pure platform play: three remaining early-stage assets share the original neuroscience-platform IP and patient-stratification approach. No commercial revenue and no near-term product launch — value rests on data readouts and partnership/M&A optionality.

NMRA-511 · Alzheimer agitation Phase 1b positive · Phase 1 MAD Q4 2026E 🟢 lead asset Selective receptor antagonist; Jan 2026 Phase 1b showed 15.7 CMAI reduction (claimed unsurpassed effect size). Competes with Rexulti (BMS) and Auvelity (Axsome). Peak sales potential $500M–$1B at 5–8% peak penetration. NMRA-898 · Schizophrenia (muscarinic) Phase 1 · data H2 2026E 🟡 to be proven Muscarinic agonist — same mechanistic class as KarXT (Bristol Myers, recently approved). Competitive but de-risked mechanism. Peak sales $400M–$700M dependent on differentiation profile. NMRA-215 · Obesity (CNS) Preclinical → Phase 1 entry 2026 🟡 early CNS-penetrant obesity asset; in preclinical models showed semaglutide-like weight loss. Highly competitive space (GLP-1, amylin) — differentiation via CNS mechanism. Optionality, not core value driver.

Monetization strategy after navacaprant failure is implicit partnership or M&A: standalone commercialization would require equity raises that severely dilute current shareholders. Successful data readouts on NMRA-511 or NMRA-898 likely trigger licensing discussions with Big Pharma (BMS, Lilly, AbbVie all active in CNS).

gavel

Legal, regulatory and risk analysis

Phase 3 trial failure

Critical (materialized)

Navacaprant KOASTAL-2/3 failed primary & key secondary endpoints in MDD. Has already happened — risk is now: securities class action filing window typical 90–180 days post-disclosure. Monitor for stockholder suits.

Binary clinical readout dependency

High

Three remaining assets are early-stage. NMRA-511 MAD data Q4 2026 and NMRA-898 data H2 2026 are both binary events — negative readouts could push stock toward bear case ($0.55–$0.85).

Securities class action

Moderate

Several plaintiff firms typically file post-Phase 3 failure when management disclosures during trial period are scrutinized. As of June 2026 no class action publicly confirmed but lead-plaintiff deadlines likely emerge Q3–Q4 2026.

Future dilution risk

Moderate

Runway into Q3 2027 — an equity raise becomes likely H1 2027 unless partnership monetizes pipeline first. At current price, raising $50M would dilute by ~18%. Shelf registration likely available.

No revenue / no near-term product

High

All assets pre-Phase 2. First commercial revenue not before 2029–2030 if any program reaches approval. Investment horizon must accommodate multi-year cash burn.

Cash floor + zero debt

Positive

$147M cash, no debt, 35% workforce cut already executed, runway extended into Q3 2027. Net cash represents ~54% of market cap — provides hard downside support at ~$0.55–$0.65/share post-burn.

CNS M&A tailwind

Positive

BMS/KarXT, Axsome/Auvelity validate CNS specialty M&A premiums. Small-cap CNS biotechs with de-risked Phase 1 assets are credible M&A targets. Patent cliffs in Big Pharma intensify scarcity premium.

Analyst coverage maintained

Positive

8 analysts cover NMRA with avg PT $7.50 (consensus Buy) post-failure. Leerink ($8), William Blair NPV $7.62, RBC $7, Mizuho $6. Coverage continuity = liquidity support and partnership exposure.

article

SWOT analysis

Strengths

+$147M cash, zero debt, runway into Q3 2027 post 35% workforce cut
+NMRA-511 Phase 1b showed clinically meaningful AD agitation effect
+Three independent shots on goal with dated readouts in H2 2026 / Q4 2026
+Net cash ~54% of mkt cap = hard floor for shareholders

Weaknesses

−Lead asset (navacaprant) failed — credibility hit and platform-thesis doubt
−Zero revenue, no near-term product launch (not before 2029–2030)
−All remaining assets are pre-Phase 2 (early data only)
−35% workforce cut may impact execution quality

Opportunities

→CNS M&A premium environment (BMS/KarXT, Axsome/Auvelity precedents)
→NMRA-511 partnership/licensing if Q4 2026 data confirms signal
→Lower opex base allows pipeline focus and longer runway
→Generalized small-cap biotech recovery if Fed cuts continue

Threats

!Negative H2 2026 / Q4 2026 readouts could trigger −40% downside
!Securities class action filings likely Q3–Q4 2026
!Equity raise H1 2027 likely if no partnership materializes
!Competitive intensity in agitation (Rexulti) and schizophrenia (KarXT)

article

Summary by assessment area

🟢 Financial risk — Low

$147M cash, zero debt
Runway into Q3 2027 post workforce cut
Net cash > 50% of market cap

🔴 Clinical/business risk — High

Lead asset failed Phase 3 — thesis reset
All remaining assets pre-Phase 2
Binary readouts H2 2026 / Q4 2026 dominate near-term direction

🟡 Risk/reward — Balanced

Cash floor ~$0.55–$0.65/share limits downside
Bull case $3.50–$5.00 requires data hits
At $1.48 the asymmetric window has narrowed vs $0.91 trough

2026-09-30 regulatory

NMRA-898 Phase 1 schizophrenia data readout

medium-term Impact: High Direction: Binary

First clinical data for muscarinic-agonist schizophrenia asset, in same class as KarXT (BMS). Positive signal validates the pipeline reset and likely triggers partnership interest; negative readout pushes stock toward cash floor.

2026-12-15 regulatory

NMRA-511 Phase 1 multiple-ascending-dose data (AD agitation)

medium-term Impact: High Direction: Binary

Key value driver post-navacaprant failure. Confirmation of the unsurpassed effect size seen in Phase 1b (15.7 CMAI reduction) would substantially de-risk the asset and likely catalyze re-rating toward $3.50–$5.00 bull scenario. Negative dose-response or tolerability issues trigger floor convergence.

2026-08-10 earnings

Q2 2026 earnings release

short-term Impact: Medium Direction: Neutral

First full quarter after the navacaprant failure and the 35% workforce cut. Investors will look for (1) confirmation of new run-rate opex (~$15M/Q), (2) extended cash runway into Q3 2027, (3) updated guidance on NMRA-511 / NMRA-898 timing.

2026-08-31 regulatory

Potential securities class action lead-plaintiff deadlines

short-term Impact: Medium Direction: Bearish

Standard 60–90 day post-disclosure window for class action filings. Public-disclosure timing of KOASTAL trial milestones may be scrutinized. Monitor PR Newswire / Bloomberg legal feeds.

2026-11-15 product

NMRA-215 CNS-obesity asset Phase 1 entry

medium-term Impact: Low Direction: Bullish

Entry into first-in-human study of obesity asset with CNS-mechanism differentiation. Optionality only — meaningful re-rating requires later-stage clinical proof.

2026-11-09 earnings

Q3 2026 earnings release

medium-term Impact: Medium Direction: Neutral

Cash position and burn trajectory check. Crucial to verify runway and assess timing of any equity raise discussions ahead of NMRA-511 Phase 1 MAD readout.

2026-12-31 partnership

Potential pipeline partnership / licensing deal

medium-term Impact: High Direction: Bullish

Following data readouts, possible licensing deal (NMRA-511 most likely candidate) with Big Pharma (BMS, Lilly, AbbVie all active in CNS). Even a $30–$50M upfront would dramatically extend runway and validate platform value.

Sources & Disclaimer

Sources: Neumora Therapeutics 8-K filings (May 2026 KOASTAL discontinuation), Q1 2026 earnings release (Globe Newswire 2026-05-07), StockAnalysis.com (price & share data), Yahoo Finance (history), TipRanks (analyst PTs), SimplyWallSt, Stocktitan. Market data — last verified close 2026-06-18: NMRA ~$1.48, market cap ~$274M, 52W: $0.61–$3.65, shares outstanding 185M. Short interest 3.9% (Fintel). Cash $147.1M (Q1 2026). No revenue. Q1 2026 EPS (0.30) vs (0.31) consensus. ⚠️ This document is for informational purposes only and does not constitute financial or investment advice.